Amendment: SEC Form SC 13G/A filed by Theravance Biopharma Inc.

$TBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $TBPH alert in real time by email
SC 13G/A 1 g610240sc13ga1.htm AMENDMENT NO. 1

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 1 – Exit Filing)*

 

Theravance Biopharma, Inc.
(Name of Issuer)
 
Ordinary Shares
(Title of Class of Securities)

 

G8807B106
(CUSIP Number)
 
May 10, 2024
(Date of Event Which Requires Filing of This Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ¨ Rule 13d-1(b)
  x Rule 13d-1(c)
  ¨ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

  
 

 

CUSIP No. G8807B106
1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

ODRE 2005 SL

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)¨

(b)¨

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Spain

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.0%

12

TYPE OF REPORTING PERSON (see instructions)

OO

 

  
 

 

CUSIP No. G8807B106
1

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

LUIS GÓMEZ LAGUNA

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

(a)¨

(b)¨

3

SEC USE ONLY

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

Spain

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH:

5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

¨

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.0%

12

TYPE OF REPORTING PERSON (see instructions)

IN

 

Item 1(a). Name of Issuer:
   
  Theravance Biopharma, Inc.
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
 

901 Gateway Boulevard

South San Francisco, CA 94080

   
Item 2(a). Name of Person Filing:
   
 

This Schedule 13G is filed jointly by:

 

(1) ODRE 2005 SL

 

(2) Luis Gómez Laguna

 

The agreement between the reporting persons relating to the joint filing of this Schedule 13G is attached hereto as Exhibit 1.

   
Item 2(b). Address of Principal Business Office or, if none, Residence:
   
  Pineta, 18B, Polígono Valdeconsejo, Nave 5, CP50410, Cuarte de Huerva (Zaragoza), Spain

 

  
 

 

Item 2(c). Citizenship:
   
  ODRE 2005 SL is sociedad limitada organized under the laws of Spain.
Mr. Gómez Laguna is a citizen of Spain.
   
Item 2(d). Title of Class of Securities:
   
  Ordinary Shares
   
Item 2(e). CUSIP Number: G8807B106

 

Item 3. Not applicable  
     
Item 4.

Ownership.

 

 

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

   
  (a) Amount Beneficially Owned: 0
       
  (b) Percent of Class: 0.0%
       
  (c) Number of shares as to which such person has:
     
    (i) sole power to vote or to direct the vote: 0
    (ii) shared power to vote or to direct the vote: 0
    (iii) sole power to dispose or to direct the disposition of: 0
    (iv) shared power to dispose or to direct the disposition of: 0

 

Item 5. Ownership of Five Percent or Less of a Class.
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

 

  
 

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.
   
  No.
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
   
  Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
   
  Not applicable.
   
Item 9. Notice of Dissolution of Group.
   
  Not applicable.
   
Item 10. Certification.
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

Exhibits:1 Joint Filing Agreement, dated as of June 11, 2024, by and between ODRE 2005 SL and Luis Gómez Laguna

 

  
 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: June 11, 2024

 

ODRE 2005 SL  
   
By: /s/ Luis Gómez Laguna  
  Name: Luis Gómez Laguna  
  Title: Director  
   
Luis Gómez Laguna  
   
By: /s/ Luis Gómez Laguna  
  Individually  

 

  
 

 

EXHIBIT 1

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13(d)-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with each other of the attached statement on Schedule 13G and to all amendments to such statement.

 

Dated: June 11, 2024

 

ODRE 2005 SL  
   
By: /s/ Luis Gómez Laguna  
  Name: Luis Gómez Laguna  
  Title: Director  
   
Luis Gómez Laguna  
   
By: /s/ Luis Gómez Laguna  
  Individually  

 

 

 

 

 

 

Get the next $TBPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TBPH

DatePrice TargetRatingAnalyst
8/6/2024$15.00 → $10.00Outperform → Market Perform
Leerink Partners
4/12/2024$21.00Buy
BTIG Research
1/8/2024Outperform → In-line
Evercore ISI
5/23/2022$12.00Outperform
SVB Leerink
3/2/2022$10.00 → $11.00Underweight
Morgan Stanley
2/24/2022$8.00 → $12.00Buy
HC Wainwright & Co.
11/5/2021$7.00 → $12.00Underweight → Neutral
JP Morgan
9/16/2021$14.00 → $10.00Underweight
Morgan Stanley
More analyst ratings

$TBPH
Press Releases

Fastest customizable press release news feed in the world

See more
  • Theravance Biopharma to Participate in an Upcoming Investor Conference

    DUBLIN, March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. To attend the fireside chat and schedule meetings with management, please contact your Jones representative or email Yuki Gonzalez, Vice President, Marketing & Corporate Access (ygonzalez@jonestrading.com). A recording

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

    DUBLIN, March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing nOH in patients with multiple system atrophy, which is currently ongoing.

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

    YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma2,3CYPRESS study on track to enroll final patient in the open label portion by mid-2025Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial an

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TBPH
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TBPH
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TBPH
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TBPH
SEC Filings

See more

$TBPH
Leadership Updates

Live Leadership Updates

See more
  • Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors

    Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and MaximizeShareholder Value DUBLIN, Dec. 21, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ:TBPH) today announced the appointment to its Board of Directors of Jeremy Grant, who serves as a Special Advisor to Irenic Capital Management LP ("Irenic"). With the addition of Mr. Grant, Theravance has appointed four new directors to the Board since 2020. "We are pleased to welcome Jeremy to the Theravance Board a

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Irenic Welcomes the Appointment of a Shareholder Representative to Theravance Biopharma's Board of Directors

    Believes Jim Kelly of Weiss Asset Management Will Bring Important Ownership Mentality to the Boardroom Encourages the Board to Continue Taking Concrete Steps to Improve Capital Allocation, Enhance Corporate Governance and Review Strategic Alternatives Irenic Capital Management, LP (together with its affiliates, "Irenic" or "we"), a top shareholder of Theravance Biopharma, Inc. (NASDAQ:TBPH) ("Theravance" or the "Company"), today issued the following statement regarding the Company's appointment of Jim Kelly, Managing Director at Weiss Asset Management, to the Board of Directors (the "Board"): "Irenic welcomes the appointment of Jim Kelly to the Theravance Board. We respect and admire

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

    DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process. "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders si

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TBPH
Financials

Live finance-specific insights

See more
  • Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

    YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma2,3CYPRESS study on track to enroll final patient in the open label portion by mid-2025Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025DUBLIN, Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced financial an

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

    DUBLIN, Ireland, Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. Conference Call Information To participate in the live call by telephone, please pre-register here. Those interested in listening to the conference call live via the internet may do so by visiting Theravance Biopharma's w

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

    Third quarter results highlight strong operational performance across key value drivers:YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241CYPRESS enrollment in-line with expectations, with timelines on trackTRELEGY net sales increased 17%, to $789 million, as reported by GSK:Q4 sales of at least ~$260 million needed to earn $25 million milestone2Q4 sales of at least ~$610 million needed to earn $50 million milestone2Board of Directors announces initiatives to unlock shareholder value and enhance corporate governanceDUBLIN, Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharm

    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

$TBPH
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more